Shanghai, China, 27 June 2022 – Fourteen of China’s top interventional came together to launch the MicroPort Argus™ OCT System at the 16th Oriental Congress of Cardiology. The online launch event titled “Vastness and diminutiveness in sight” was hosted by Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”).
Compared with conventional non-endoluminal imaging techniques such as digital subtraction angiography (DSA), endoluminal imaging techniques, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS) are widely considered essential in optimizing percutaneous coronary intervention (PCI). OCT is the highest resolution intracavitary imaging available, providing interventional cardiologists with images of finer microstructural features of the intima and support in precise diagnosis.
Academic Runlin Gao from Fuwai Hospital of the Chinese Academy of Medical Sciences said at the launch event that OCT as a key endoluminal imaging technology features the highest resolution, which helps doctors to customize treatment for different patients. He also described OCT as "optical biopsy" and the new gold standard for the diagnosis of coronary heart disease. He said, “With the launch of China's homegrown MicroPort Argus™ OCT system, we believe that in the future, China will become the first in the world in the field of interventional cardiology not only in terms of quantity, but also in terms of device development as well as theoretical and technological innovation, which will definitely reach international leading levels.”
Academic Junbo Ge of Zhongshan Hospital of Fudan University, said that the launch of the MicroPort Argus™ OCT system not only represents a new breakthrough in the field of OCT in China through independent innovation and research, but also marks a solid first step in accelerating the process of localization of medical devices in our country. “We hope that, in collaboration with China’s clinical experts, MicroPort Argus™ can promote the popularity of OCT and the development of precision PCI with more and better innovative products to benefit more patients in the future.”
Prof. Juying Qian from Zhongshan Hospital of Fudan University shared her experience with MicroPort Argus™ OCT System. She commented that, in practicing continuous innovation, MicroPort® was able to independently develop the proprietary OCT endoluminal imaging system and China’s only purge-free OCT imaging catheter, which lend a superior "golden eye" to clinical experts and opened a new era of precision PCI.
Mr. Lei Jiang, President of MicroPort® Coronary, also brought his perspective to the event: “Focusing on the OCT system solution, we have made breakthroughs and obtained several first-of-its-kind technologies in the field of OCT, and have filed over 50 patent applications, which results in the development of the MicroPort Argus™ OCT system, the only purge-free OCT imaging catheter in China. MicroPort® has always carried its mission and responsibility to provide targeted innovation based on clinical needs. We insist on independent research and development to deepen medical–industrial cooperation and unlock the power of innovation. By providing more innovative technologies and superior products, we will be able to provide accessible and inclusive solution to prolong and reshape the lives of patients with coronary heart disease.”
About Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the Future, MicoPort® will continue to steadily promote the target global clinical research program, enrich the cardiovascular interventional therapy product line with the support of accumulated clinical research data, and provide patients with more high-quality and inclusive integrated solutions.